An isolated antibody that binds to an extracellular domain of ferroportin (SEQ ID NO: 16) and that preserves ferroportin activity in the presence of hepcidin, wherein the antibody comprises: (i) an amino acid sequence at least 90% identical to SEQ ID NOs: 2 or 4, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 5-10 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 5-10; (ii) an amino acid sequence at least 90% identical to SEQ ID NOs: 26 or 28, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 29-34 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 29-34; (iii) an amino acid sequence at least 90% identical to SEQ ID NOs: 36 or 38, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 39-44 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 39-44; (iv) an amino acid sequence at least 90% identical to SEQ ID NOs: 46 or 48, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 49-54 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 49-54; (v) an amino acid sequence at least 90% identical to SEQ ID NOs: 56 or 58, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 59-64 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 59-64; (vi) an amino acid sequence at least 90% identical to SEQ ID NOs: 66 or 68, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 69-74 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 69-74; (vii) an amino acid sequence at least 90% identical to SEQ ID NOs: 76 or 78, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 79-84 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 79-84; (viii) an amino acid sequence at least 90% identical to SEQ ID NOs: 86 or 88, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 89-94 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 89-94; (ix) an amino acid sequence at least 90% identical to SEQ ID NOs: 96 or 98, said amino acid sequence comprising at least CDR selected from the group consisting of SEQ ID NOs: 99-104 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 99-104; or (x) an amino acid sequence at least 90% identical to SEQ ID NOs: 106 or 108, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 109-114 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 109-114. (i) an amino acid sequence at least 90% identical to SEQ ID NOs: 2 or 4, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 5-10 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 5-10; (ii) an amino acid sequence at least 90% identical to SEQ ID NOs: 26 or 28, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 29-34 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 29-34; (iii) an amino acid sequence at least 90% identical to SEQ ID NOs: 36 or 38, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 39-44 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 39-44; (iv) an amino acid sequence at least 90% identical to SEQ ID NOs: 46 or 48, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 49-54 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 49-54; (v) an amino acid sequence at least 90% identical to SEQ ID NOs: 56 or 58, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 59-64 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 59-64; (vi) an amino acid sequence at least 90% identical to SEQ ID NOs: 66 or 68, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 69-74 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 69-74; (vii) an amino acid sequence at least 90% identical to SEQ ID NOs: 76 or 78, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 79-84 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 79-84; (viii) an amino acid sequence at least 90% identical to SEQ ID NOs: 86 or 88, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 89-94 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 89-94; (ix) an amino acid sequence at least 90% identical to SEQ ID NOs: 96 or 98, said amino acid sequence comprising at least CDR selected from the group consisting of SEQ ID NOs: 99-104 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 99-104; or (x) an amino acid sequence at least 90% identical to SEQ ID NOs: 106 or 108, said amino acid sequence comprising at least one CDR selected from the group consisting of SEQ ID NOs: 109-114 and any CDRs comprising at least one amino acid change to any of SEQ ID NOs: 109-114.